Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public offering nets $55.4mm for Veracyte

Executive Summary

Veracyte Inc. publicly sold 5.75mm common shares (including the overallotment) at $10.25 apiece for net proceeds of $55.4mm. The company markets genomic tests for thyroid cancer (Afirma), lung cancer (Percepta), and idiopathic pulmonary fibrosis (Envisia).
Deal Industry
  • In Vitro Diagnostics
    • Cytology
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies